Heart Failure Beat: Driving Heart Failure Care Forward: HFSA’s Vision for 2025 with President Dr. Michael Felker

On this episode of HF Beat, Michael Felker, MD, FHFSA, current HFSA President shares the vision for HFSA over the coming year, focusing on advancing research, engaging patients, and inspiring future heart failure specialists. Tune in to hear about new initiatives for personalized treatments, team-based care, and overcoming challenges like therapy access.

Driving Heart Failure Care Forward: HFSA’s Vision for 2025 with President Dr. Michael Felker

On this episode of HF Beat, Michael Felker, MD, FHFSA, current HFSA President, shares HFSA’s vision for the coming year, highlighting initiatives to expand patient and caregiver engagement, bolster research funding through the Heart Failure Research Foundation, and inspire the next generation of heart failure specialists. The discussion delves into the challenges and opportunities in heart failure care, from improving access to therapies like GLP-1 agonists to personalizing multi-drug treatments for patients with HFpEF. Dr. Felker also emphasizes the critical role of fostering teamwork across healthcare providers and patients to address the growing heart failure epidemic. Tune in for insights on advancing education, research, and collaboration to meet the challenges of tomorrow.

Listen below and subscribe: Apple PodcastsAmazon Music, SpotifyPodcast Home

Featuring

Hosts: 

  • Michael Beasley, MD, Assistant Professor of Medicine at the Yale School of Medicine @MHBeasleyMD

  • Priya Umapathi, MD, Assistant Professor in the Division of Cardiology & Advanced Heart Failure and Heart Transplant Cardiologist at Johns Hopkins Hospital @priyaumapathi

Guest: 

  • Michael Felker, MD, FHFSA, Professor of Medicine at Duke University School of Medicine @DukeHFDoc
     


Guest Disclosures

Dr. Felker has received research grants from NIH, Bayer, BMS,  Novartis, Daxor, Merck, Cytokinetics, and CSL-Behring; he has acted as a consultant to Novartis, BMS, Cytokinetics, Boehringer-Ingelheim, Abbott, Sanofi, Regeneron, Myovant, Sequana, and Whiteswell, and has served on clinical endpoint committees/data safety monitoring boards for Merck, Medtronic, EBR Systems, Rocket Pharma, V-Wave, LivaNova